34 initial public offerings have been priced so far this year as of Feb 10, 2006:

- 20 IPOs are currently trading above initial offering price;
- 6 are trading below the offering price;
- and 8 are trading at their offer price.

A total of nine IPOs were priced during the week of February 6th, 2006. There are two deals scheduled to be priced during the coming week, hoping to raise nearly $500 million.

IPO PERFORMANCE

ADVANCERS:

Crocs Inc. (CROX: chart) priced 9.9 million shares at $21 per share on Thursday. The price came above the expected range of $19 - $20. On Monday the company increased the number of shares from the original filing of 9 million and its price forecast from an earlier range of $13 - $15 per share. The offering was worth $207.9 million.

Crocs offered 4.95 million shares of common stock and selling stockholders sold the remaining 4.95 million shares.

In addition, the selling stockholders have granted the underwriters a 30-day option to purchase up to 1.5 million additional shares to cover over-allotments.

Piper Jaffray and Thomas Weisel were the lead managers with SG Cowen, BB&T Capital Markets, D.A. Davidson and Wedbush Morgan Securities serving as co-managers for the offering.

The Niwot, Colorado-based company started selling its resin shoes in 2002, and rapidly became a cult hit in its home state.

Crocs reported net income attributable to common shareholders of $12.6 million on $75 million in sales for the nine months ended Sept. 30, compared with a net loss of $627,000 on sales of $8.1 million a year ago.

Crocs debut is the second strong performance on the U.S. IPO market this year for a Colorado-based company. Last month, shares of Denver-based Chipotle Mexican Grill (CMG: chart) gained 100% in their first day on the New York Stock Exchange.

The stock closed the first day at $28.55, and ended the week at $26.55, up 26.4% from the offering price.

Drugmaker Acorda Therapeutics Inc. (ACOR: chart) priced 5.5 million shares at $6 per share on Friday. The price came at the low end of the revised range of $6 - $7 filing. The original filing was within $11 - $13 per share. The offer was worth $33 million.

All of the shares were offered by Acorda Therapeutics.

Banc of America Securities managed the deal. Lazard Capital Markets, Piper Jaffray and SG Cowen acted as co-managers.

The Hawthorne, New York-based company makes a drug used to treat spasticity, a condition characterized by stiffness and painful muscle spasms and is developing other treatments for problems related to multiple sclerosis.

The stock closed the first day and the week at $6.72, up 12% from the offering price.

Energy exploration company EXCO Resources Inc. (XCO: chart) priced 50 million shares at $13 per share on Thursday at the high end of the $11 - $13 filing. The deal, representing a 50% stake in the company, was worth $650 million. All of the shares were sold by the company.

J.P. Morgan was the lead underwriter and J.P. Morgan , Bear Stearns and Goldman Sachs acted as co-managers for this offering.